Item 1. Financial Statements
ITEM
1 Financial Statements
BTCS
Inc.
Condensed
Balance Sheets
September
30,
December
31,
2021
2020
(Unaudited)
Assets:
Current
assets:
Cash
$ 658,931
$ 524,135
Digital
assets/currencies
3,159,976
995,652
Prepaid
expense
472,389
31,875
Total
current assets
4,291,296
1,551,662
Other
assets:
Property
and equipment, net
4,330
230
Staked
digital assets/currencies
8,838,046
-
Total
other assets
8,842,376
230
Total
Assets
$ 13,133,672
$ 1,551,892
Liabilities
and Stockholders’ Equity:
Accounts
payable and accrued expense
$ 102,122
$ 26,288
Accrued
compensation
1,501
350,376
Convertible
notes payable, net
848,685
131,941
Warrant
liabilities
3,705,000
-
Total
current liabilities
4,657,308
508,605
Stockholders’
equity:
Preferred
stock; 20,000,000 shares authorized at $ 0.001 par value:
-
Series
C-1 Convertible Preferred stock: 0 and 29,414 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively;
Liquidation preference $ 0.001 per share
-
29
Series
C-2 Convertible Preferred stock: 0 shares issued and outstanding at September 30, 2021 and December 31, 2020; Liquidation preference
$ 0.001 per share
-
-
Common
stock, 97,500,000 shares authorized at $ 0.001 par value, 10,102,711 and 4,201,035 shares issued and outstanding at September 30,
2021 and December 31, 2020, respectively
10,103
4,201
Additional
paid in capital
143,472,733
120,578,944
Accumulated
deficit
( 135,006,472 )
( 119,539,887 )
Total
stockholders’ equity
8,476,364
1,043,287
Total
Liabilities and stockholders’ equity
$ 13,133,672
$ 1,551,892
The
accompanying notes are an integral part of these unaudited condensed financial statements.
4
BTCS
Inc.
Condensed
Statements of Operations
(Unaudited)
Three
Months Ended
September 30,
Nine
Months Ended
September 30,
2021
2020
2021
2020
Revenues
Validator
revenue
$ 323,376
$ -
$ 776,399
$ -
Total
revenues
323,376
-
776,399
-
Cost
of revenues
Validator
expense
71,690
-
145,935
-
Gross
profit
251,686
-
630,464
-
Operating
expenses:
General
and administrative
$ 282,558
$ 650,049
$ 1,149,506
$ 935,118
Research
and development
273,909
-
602,178
-
Compensation
and related expenses
4,747,106
228,540
13,788,556
469,935
Marketing
7,559
1,365
10,345
5,420
Total
operating expenses
5,311,132
879,954
15,550,585
1,410,473
Other
(expenses) income:
Interest
expense
( 58,521 )
( 96,068 )
( 172,603 )
( 35,289 )
Amortization
on debt discount
( 581,973 )
-
( 1,716,744 )
( 186,199 )
Change
in fair value of warrant liabilities
2,066,250
-
2,066,250
-
Impairment
loss on digital assets/currencies
( 208,647 )
( 29,302 )
( 3,777,785 )
( 162,254 )
Realized
gains (loss) on digital asset/currency transactions
-
-
3,054,418
( 1,682 )
Total
other income (expenses)
1,217,109
( 125,370 )
( 546,464 )
( 385,424 )
Net
loss
$ ( 3,842,337 )
$ ( 1,005,324 )
$ ( 15,466,585 )
$ ( 1,795,897 )
Deemed
dividends related to amortization of beneficial conversion feature of Series C-2 convertible preferred stock
( 13,188 )
-
( 45,541 )
-
Deemed
dividends related to recognition of downround adjustment to conversion amount for Series C-2 convertible preferred stock
-
-
( 5,020,883 )
-
Net
loss attributable to common stockholders
$ ( 3,855,525 )
$ ( 1,005,324 )
$ ( 20,533,009 )
$ ( 1,795,897 )
Net
loss per share attributable to common stockholders, basic and diluted
$ ( 0.59 )
$ ( 0.33 )
$ ( 3.63 )
$ ( 0.66 )
Weighted
average number of common shares outstanding, basic and diluted
6,518,645
3,083,246
5,660,966
2,700,947
The
accompanying notes are an integral part of these unaudited condensed financial statements.
5
BTCS
Inc.
Statements
of Changes in Stockholders’ (Deficit) Equity
(Unaudited)
For
the Three Months Ended September 30, 2021
Series
C-1 Convertible
Series
C-2 Convertible
Additional
Total
Stockholders’
Preferred
Stock
Preferred
Stock
Common
Stock
Paid-in
Accumulated
Equity
Shares
Amount
Shares
Amount
Shares
Amount
Capital
Deficit
(Deficit)
Balance
June 30, 2021
-
$ -
1,100,000
$ 6,203,101
5,712,215
$ 5,712
$ 137,959,473
$ ( 131,164,135 )
$ 13,004,151
Common
stock issued including equity commitment fee, net
-
-
-
-
32,963
33
199,839
-
199,872
Conversion
of convertible notes
Conversion
of convertible notes, shares
Beneficial conversion features associated with convertible notes payable
Issuance
of common stock, net of offering cost / At-the-market offering
-
-
-
-
41,290
41
219,705
-
219,746
Issuance
of common stock and warrants for cash, net
Issuance
of common stock and warrants for cash, net , shares
Warrant
liabilities value related to Issuance of common stock
-
-
-
-
( 5,771,250 )
-
( 5,771,250 )
Issuance
of Series C-2 convertible preferred stock
Issuance
of Series C-2 convertible preferred stock , shares
Conversion
of Series C-2 Convertible Preferred stock
( 1,100,000 )
( 6,216,289 )
4,011,766
4,012
6,212,277
-
-
Deemed
dividends related to amortization of beneficial conversion feature of Series C-2 convertible preferred stock
-
-
-
13,188
-
-
( 13,188 )
-
-
Conversion
of Series C-1 Convertible Preferred stock
Conversion
of Series C-1 Convertible Preferred stock, shares
Beneficial
conversion features associated with convertible notes payable
Beneficial
conversion feature of Series C-2 convertible preferred stock
Deemed
dividends related to amortization of beneficial conversion feature of Series C-2 convertible preferred stock
Deemed
dividends related to recognition of downround adjustment to conversion amount for Series C-2 convertible preferred stock
Fractional
shares adjusted for reverse split
-
14,477
15
( 15 )
-
-
Warrant
exercise
Warrant
exercise , shares
Stock-based
compensation
-
-
-
-
290,000
290
4,665,892
-
4,666,182
Stock-based
compensation in connection with issuance of Series C-2 convertible preferred stock
Net
loss
-
-
-
-
-
-
-
( 3,842,337 )
( 3,842,337 )
Balance
September 30, 2021
-
$ -
-
$ -
10,102,711
$ 10,103
$ 143,472,733
$ ( 135,006,472 )
$ 8,476,364
For
the Three Months Ended September 30, 2020
Series
C-1 Convertible
Additional
Total
Stockholders’
Preferred
Stock
Common
Stock
Paid-in
Accumulated
Equity
Shares
Amount
Shares
Amount
Capital
Deficit
(Deficit)
Balance
June 30, 2020
29,414
$ 29 -
2,819,025
$ 2,819
$ 117,834,086
$ ( 117,774,366 )
$ 62,568
Common
stock issued including equity commitment fee, net
-
-
485,395
485
828,796
-
829,281
Net
loss
-
- -
-
-
-
( 1,005,324 )
( 1,005,324 )
Balance
September 30, 2020
29,414
$ 29 -
3,304,420
$ 3,304
$ 118,662,882
$ ( 118,779,690 )
$ ( 113,475 )
For
the Nine Months Ended September 30, 2021
Series
C-1 Convertible
Series
C-2 Convertible
Additional
Total
Stockholders’
Preferred
Stock
Preferred
Stock
Common
Stock
Paid-in
Accumulated
(Deficit)
Shares
Amount
Shares
Amount
Shares
Amount
Capital
Deficit
Equity
Balance
December 31, 2020
29,414
$ 29
-
$ -
4,201,035
$ 4,201
$ 120,578,944
$ ( 119,539,887 )
$ 1,043,287
Common
stock issued including equity commitment fee, net
-
-
-
-
321,738
322
3,013,683
-
3,014,005
Issuance
of common stock, net of offering cost / At-the-market offering
-
-
-
-
41,290
41
219,705
-
219,746
Issuance
of common stock and warrants for cash, net
-
-
-
-
950,000
950
8,864,050
-
8,865,000
Warrant
liabilities value related to Issuance of common stock
-
-
-
-
-
-
( 5,771,250 )
-
( 5,771,250 )
Issuance
of Series C-2 convertible preferred stock
-
-
1,100,000
1,100,000
-
-
-
-
1,100,000
Conversion
of Series C-1 Convertible Preferred stock
( 29,414 )
( 29 )
-
-
19,609
20
9
-
-
Conversion
of Series C-2 Convertible Preferred stock
-
-
( 1,100,000 )
( 6,216,289 )
4,011,766
4,012
6,212,277
-
-
Beneficial
conversion features associated with convertible notes payable
-
-
-
-
-
-
1,000,000
-
1,000,000
Beneficial
conversion feature of Series C-2 convertible preferred stock
-
-
-
( 129,412 )
-
-
129,412
-
-
Deemed
dividends related to amortization of beneficial conversion feature of Series C-2 convertible preferred stock
-
-
-
45,541
-
-
( 45,541 )
-
-
Deemed
dividends related to recognition of downround adjustment to conversion amount for Series C-2 convertible preferred stock
-
-
-
5,020,883
-
-
( 5,020,883 )
-
-
Fractional
shares adjusted for reverse split
-
-
14,477
15
( 15 )
-
-
Warrant
exercise
-
-
-
-
200,000
200
399,800
-
400,000
Stock-based
compensation
-
-
-
-
342,796
342
13,892,542
-
13,892,884
Stock-based
compensation in connection with issuance of Series C-2 convertible preferred stock
-
-
-
179,277
-
-
-
-
179,277
Net
loss
-
-
-
-
-
-
-
( 15,466,585 )
( 15,466,585 )
Balance
September 30, 2021
-
$ -
-
$ -
10,102,711
$ 10,103
$ 143,472,733
$ ( 135,006,472 )
$ 8,476,364
For
the Nine Months Ended September 30, 2020
Series
C-1 Convertible
Additional
Total
Preferred
Stock
Common
Stock
Paid-in
Accumulated
Stockholders’
Shares
Amount
Shares
Amount
Capital
Deficit
Deficit
Balance
December 31, 2019
29,414
$ 29 -
1,983,047
$ 1,983
$ 116,798,021
$ ( 116,983,793 )
$ ( 183,760 )
Balance
29,414
$ 29 -
1,983,047
$ 1,983
$ 116,798,021
$ ( 116,983,793 )
$ ( 183,760 )
Common
stock issued including equity commitment fee, net
-
-
1,180,989
1,181
1,384,313
-
1,385,494
Conversion
of convertible notes
-
-
140,384
140
211,317
-
211,457
Beneficial
conversion features associated with convertible notes payable
-
-
-
-
269,231
-
269,231
Net
loss
-
- -
-
-
-
( 1,795,897 )
( 1,795,897 )
Balance
September 30, 2020
29,414
$ 29 -
3,304,420
$ 3,304
$ 118,662,882
$ ( 118,779,690 )
$ ( 113,475 )
Balance
29,414
$ 29 -
3,304,420
$ 3,304
$ 118,662,882
$ ( 118,779,690 )
$ ( 113,475 )
The
accompanying notes are an integral part of these unaudited condensed financial statements.
6
BTCS
Inc.
Condensed
Statements of Cash Flows
(Unaudited)
2021
2020
For
the Nine Months Ended
September
30,
2021
2020
Net
Cash flows used from operating activities:
Net
loss
$ ( 15,466,585 )
$ ( 1,795,897 )
Adjustments
to reconcile net loss to net cash used in operating activities:
Depreciation
expense
443
895
Amortization
on debt discount
1,716,744
186,199
Stock-based
compensation
13,892,884
-
Stock-based
compensation in connection with issuance of Series C-2 convertible preferred stock
179,277
Validator
revenue
( 776,399 )
-
Change
in fair value of warrant liabilities
( 2,066,250 )
Purchase
of non-productive digital assets/currencies
( 5,761,550 )
( 808,355 )
Sale
of non-productive digital assets/currencies
4,274,491
-
Realized
gain on digital assets/currencies transactions
( 3,054,418 )
-
Impairment
loss on digital assets/currencies
3,777,785
162,254
Changes
in operating assets and liabilities:
Prepaid
expenses and other current assets
( 440,514 )
( 11,466 )
Accounts
payable and accrued expenses
168,546
13,015
Accrued
compensation
( 348,875 )
589,466
Net
cash used in operating activities
( 3,904,421 )
( 1,663,889 )
Net
cash used in investing activities:
Purchase
of productive digital assets/currencies for validating
( 9,462,279 )
-
Purchase
of property and equipment
( 4,543 )
-
Net
cash used in investing activities
( 9,466,822 )
-
Net
cash provided by financing activities:
Proceeds
from short term loan
-
500,000
Proceeds
from exercise of warrants
400,000
-
Proceeds
from issuance of Series C-2 convertible preferred stock
1,100,000
-
Net
proceeds from issuance of convertible notes
1,000,000
-
Net
proceeds from issuance of common stock and warrants for cash
8,865,000
-
Net
proceeds from issuance of common stock
3,014,005
1,385,494
Net
proceeds from issuance common stock/ At-the-market offering
219,746
-
Payment
to convertible notes principle and accrued interest
( 1,092,712 )
-
Net
cash provided by financing activities
13,506,039
1,885,494
Net
increase in cash
134,796
221,605
Cash,
beginning of period
524,135
143,098
Cash,
end of period
$ 658,931
$ 364,703
Supplemental
disclosure of non-cash financing and investing activities:
Deemed
dividends related to amortization of beneficial conversion feature of Series C-2 convertible preferred stock
$ 45,541
$ -
Deemed
dividends related to recognition of downround adjustment to conversion amount for Series C-2 convertible preferred stock
$ 5,020,883
$ -
Conversion
of Series C-1 Preferred Stock
$ 20
$ -
Conversion
of Series C-1 Preferred Stock
$ 6,216,289
Beneficial
conversion feature of Series C-2 convertible preferred stock
$ 129,412
$ -
Beneficial
conversion features associated with convertible notes payable
$ 1,000,000
$ 269,231
Conversion
of convertible note to common stock
$ -
$ 211,457
The
accompanying notes are an integral part of these unaudited condensed financial statements.
7
BTCS
Inc.
Notes
to Unaudited Condensed Financial Statements
Note
1 - Business Organization and Nature of Operations
BTCS
Inc. (formerly Bitcoin Shop, Inc.), a Nevada corporation (the “Company”) was incorporated in 2008. In February 2014, the
Company entered the business of hosting an online e-commerce marketplace where consumers could purchase merchandise using digital assets,
including Bitcoin. The Company is currently focused on blockchain and digital currency ecosystems. In late 2014 we shifted our focus
towards our transaction verification service business, also known as bitcoin mining, though in mid-2016 we ceased our mining operation
at our North Carolina facility due to capital constraints. In January 2015, the Company began a rebranding campaign using its BTCS.com
domain to better reflect its broadened strategy. The Company recently released its new website which included broader information on
its strategy.
In
the first quarter of 2021, the Company resumed its blockchain infrastructure operations (previously referred to as transaction verification
services) with a focus on securing proof-of-stake blockchains and anticipates this will be a core focus going forward. Blockchain infrastructure
operations can broadly be defined as earning a reward for securing a blockchain by validating transactions on that blockchain. The Company
is developing a proprietary staking-as-a-service platform that would enable clients to stake and delegate supported cryptocurrencies
through a non-custodial platform.
The
Company is also developing a proprietary digital asset data analytics platform aimed at enabling users to aggregate their portfolio holdings
from multiple exchanges and wallets into a single platform to view and analyze performance, risk metrics, and potential tax implications.
The internally developed platform utilizes digital asset exchange APIs to read user data and does not allow for the trading of assets.
The
Company employs a digital asset treasury strategy with a primary focus on disruptive non-security protocol layer assets such as Bitcoin
and Ethereum. The Company receives digital assets from its blockchain infrastructure business and acquires digital assets through open
market purchases. The Company is not limiting its assets to a single type of digital asset and may hold a variety of digital assets.
The Company will carefully review its purchases of digital securities to avoid violating the 1940 Act and seek to reduce potential liabilities
under the federal securities laws.
The
market is rapidly evolving and there can be no assurances that we will be competitive with industry participants that have or may have
greater resources than us.
Amendment
to Articles of Incorporation
On
August 12, 2021, the Company filed a Certificate of Change with the Nevada Secretary of State to affect a 1-for-10 reverse split of the
Company’s class of common stock (the “Reverse Split”). The Certificate of Change became effective on August 13, 2021.
No
fractional shares were issued in connection with the Reverse Split and all such fractional interests were rounded up to the nearest whole
number of shares of common stock. The Company now has 97,500,000 shares of common stock authorized. Numbers of shares of the Company’s
preferred stock were not affected by the Reverse Split; however, the conversion ratios have been adjusted to reflect the Reverse Split.
The financial statements have been retroactively restated to reflect the Reverse Split.
8
Note
2 - Basis of Presentation
The
accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted
in the United States (“GAAP”) for interim financial information, the instructions to Form 10-Q and the rules and regulations
of the SEC. Accordingly, since they are interim statements, the accompanying unaudited condensed financial statements do not include
all of the information and notes required by GAAP for annual financial statements, but in the opinion of the Company’s management,
reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair presentation of the financial position,
results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of results for
a full year. The unaudited condensed financial statements and notes should be read in conjunction with the financial statements and notes
for the year ended December 31, 2020.
Note
3 - Liquidity, Financial Condition and Management’s Plans
The
Company has commenced its planned operations but has limited operating activities to date. The Company has financed its operations since
inception using proceeds received from investments from third-party investors as well as from officers and directors of the Company.
The Company has plans to continue to raise proceeds from sale of common stock and issuance of debt to fund operations as needed
for the next twelve months.
During
the nine months ended September 30, 2021, the Company received net proceeds of approximately $ 14.6
million from the issuance of: Series C-2 convertible
preferred stock, a convertible note, common stock and warrants issued pursuant to the Purchase agreement, common stock issued pursuant
to the Equity Line Purchase Agreement, the cash exercise of warrants, and the proceeds from the common stock sold pursuant to the ATM
Agreement. On September 30, 2021, the fair market value of the Company’s liquid digital assets was approximately $ 6.2
million and the Company had approximately
$ 0.66 million of cash. As such, the Company has adequate cash to fund operations for at least the next twelve months.
Note
4 - Summary of Significant Accounting Policies
There
have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2020 Annual
Report.
Validator
Revenue
The
Company runs its own digital asset validator nodes and has entered into network-based smart contracts. Through these contracts, the Company
provides cryptocurrency to stake a node for the purpose of validating transactions and adding blocks to a respective blockchain network.
The term of a smart contract can vary based on the rules of the respective blockchain and typically last a few weeks to months after
it is cancelled by the operator and requires that the cryptocurrency staked remain locked up during the duration of the smart contract.
In exchange for validating transactions and staking the cryptocurrency, the Company is entitled to all of the fixed cryptocurrency award
for running the Company’s own node and successfully processing, validating and/or adding a block to the blockchain.
The
provision of validating blockchain transactions is an output of the Company’s ordinary activities. Each separate block creation
or validation under a smart contract with a network represents a performance obligation. The transaction consideration the Company receives
– the fixed cryptocurrency awards – is a non-cash consideration, which the Company measures at fair value on the date received.
The fair value of the cryptocurrency award received is determined using the quoted price of the related cryptocurrency on the date of
receipt. The satisfaction of the performance obligation for processing and validating blockchain transactions occurs at a point in time
when confirmation is received from the network indicating that the validation is complete, and the awards are available for transfer.
At that point, revenue is recognized.
Cost
of Revenue
The
Company’s cost of revenue consists primarily of direct production costs related to the operations of validating transactions on
the network, rent and utilities for locations housing server nodes to the extent applicable, hosting costs if cloud-based servers are
utilized and fees (including stock-based fees) paid to 3rd parties to assist in the software maintenance and operations of its nodes.
9
Digital
Assets Translations and Impairments
Digital
assets are included in the balance sheets as either current assets or other assets if they are staked and locked up for over one year.
Digital assets are recorded at cost less impairment.
An
intangible asset with an indefinite useful life is not amortized but assessed for impairment annually, or more frequently, when events
or changes in circumstances occur indicating that it is more likely than not that the indefinite-lived asset is impaired. Impairment
exists when the carrying amount exceeds its fair value. In testing for impairment, the Company has the option to first perform a qualitative
assessment to determine whether it is more likely than not that an impairment exists. If it is determined that it is not more likely
than not that an impairment exists, a quantitative impairment test is not necessary. If the Company concludes otherwise, it is required
to perform a quantitative impairment test. To the extent an impairment loss is recognized, the loss establishes the new cost basis of
the asset. Subsequent reversal of impairment losses is not permitted.
Realized
gain (loss) on sale of digital assets are included in other income (expense) in the statements of operations. We assign costs to transactions
on a first-in, first-out basis.
The
Company assesses impairment of digital assets quarterly if the fair value of digital assets is less than its cost basis. The Company
recognizes impairment losses on digital assets caused by decreases in fair value using the lowest U.S. dollar spot price of the related
digital asset as of each impairment date. Such impairment in the value of digital assets are recorded as a component of costs and expenses
in our statements of operations.
Internally
Developed Software
Internally
developed software consisting of the core technology of the Company’s digital asset data analytics platform which is being designed
to allow user to aggregate and analyze data from digital asset exchanges. For internally developed software, the Company uses both its
own employees as well as the services of external vendors and independent contractors. The Company accounts for computer software used
in the business in accordance with ASC 985-20 and ASC 350.
ASC
985-20, Software-Costs of Computer Software to Be Sold, Leased, or Otherwise Marketed, requires that software development costs
incurred in conjunction with product development be charged to research and development expense until technological feasibility is established.
Thereafter, until the product is released for sale, software development costs must be capitalized and reported at the lower of unamortized
cost or net realizable value of the related product. Some companies use a “tested working model” approach to establishing
technological feasibility (i.e., beta version). Under this approach, software under development will pass the technological feasibility
milestone when the Company has completed a version that contains essentially all the functionality and features of the final version
and has tested the version to ensure that it works as expected.
ASC
350, Intangibles-Goodwill and Other , requires computer software costs associated with internal use software to be charged to operations
as incurred until certain capitalization criteria are met. Costs incurred during the preliminary project stage and the post-implementation
stages are expensed as incurred. Certain qualifying costs incurred during the application development stage are capitalized as property,
equipment, and software. These costs generally consist of internal labor during configuration, coding, and testing activities. Capitalization
begins when (i) the preliminary project stage is complete, (ii) management with the relevant authority authorizes and commits to the
funding of the software project, and (iii) it is probable both that the project will be completed and that the software will be used
to perform the function intended.
Use
of Estimates
The
accompanying unaudited condensed financial statements have been prepared in conformity with GAAP. This requires management to make estimates
and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at
the date of the financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant
estimates and assumptions include the recoverability and useful lives of intangible assets, stock-based compensation, the valuation of
derivative liabilities, the valuation of convertible preferred stock and the valuation allowance related to the Company’s deferred
tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, if any, could be affected
by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external
factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.
10
Accounting
for Warrants
The
Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with
the provisions of ASC 815, Derivatives and Hedging (“ASC 815”). The Company classifies as equity any contracts that (i) require
physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares
(physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash
settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the
Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).
In addition, Under ASC 815, registered common stock warrants that require the issuance of registered shares upon exercise and do not
expressly preclude an implied right to cash settlement are accounted for as derivative liabilities. The Company classifies these derivative
warrant liabilities on the balance sheet as a current liability.
The
Company assessed the classification of common stock purchase warrants as of the date of each offering and determined that such instruments
originally met the criteria for equity classification; however, as a result of the Company no longer being in control of whether the
warrants may be cash settled, the instruments no longer qualify for equity classification. Accordingly, the Company classified the warrants
as a liability at their fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement
at each balance sheet date until the warrants are exercised or expired, and any change in fair value is recognized as “change in
the fair value of warrant liabilities” in the statements of operations. The fair value of the warrants has been estimated
using a Black-Scholes valuation model (see Note 6).
Stock-based
Compensation
The
Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options
issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price
of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options often vest over a
one-year period.
The
Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating
the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application
of management’s judgment.
Expected
Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding
based on the simplified method, which is the half-life from vesting to the end of its contractual term.
Expected
Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.
Risk-Free
Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues
with an equivalent remaining term.
Expected
Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends
in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.
Effective
January 1, 2017, the Company elected to account for forfeited awards as they occur, as permitted by ASU 2016-09. Ultimately, the actual
expenses recognized over the vesting period will be for those shares that vested. Prior to making this election, the Company estimated
a forfeiture rate for awards at 0 %, as the Company did not have a significant history of forfeitures.
11
Convertible
Preferred Stock
The
Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement
of its preferred stock. Preferred stock subject to mandatory redemption are classified as liability instruments and are measured at fair
value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the
control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control)
are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ equity. The Company evaluated
the classification of its convertible preferred stock and determined that such instruments meet the criteria for equity classification.
The
Company has also evaluated its convertible preferred stock in accordance with the provisions of ASC 815, Derivatives and Hedging ,
including consideration of embedded derivatives requiring bifurcation. The issuance of the convertible preferred stock could generate
a beneficial conversion feature, which arises when a debt or equity security is issued with an embedded conversion option that is beneficial
to the investor or in the money at inception because the conversion option has an effective strike price that is less than the market
price of the underlying stock at the commitment date.
Beneficial
Conversion Feature of Convertible Notes Payable
The
Company accounts for convertible notes payable in accordance with the guidelines established by the FASB Accounting Standards Codification
(“ASC”) Topic 470-20, Debt with Conversion and Other Options. The beneficial conversion feature of a convertible note is
normally characterized as the convertible portion or feature of certain notes payable that provide a rate of conversion that is below
market value or in-the-money when issued. The Company records a beneficial conversion feature related to the issuance of a convertible
note when issued.
The
discounted face value is then used to measure the effective conversion price of the note. The effective conversion price and the market
price of the Company’s common stock are used to calculate the intrinsic value of the conversion feature. The intrinsic value is
recorded in the financial statements as a debt discount from the face amount of the note and such discount is amortized over the expected
term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Net
Loss per Share
Basic
loss per share is computed by dividing the net income or loss applicable to common shares by the weighted average number of common shares
outstanding during the period. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive,
potential common shares outstanding during the period. Potential common shares consist of the Company’s convertible preferred stock,
convertible notes and warrants. Diluted loss per share excludes the shares issuable upon the conversion of preferred stock, notes and
warrants from the calculation of net loss per share if their effect would be anti-dilutive.
The
following financial instruments were not included in the diluted loss per share calculation as of September 30, 2021 and 2020 because
their effect was anti-dilutive:
Schedule
of Earnings Per Share Anti-diluted
As
of September 30,
2021
2020
Warrants
to purchase common stock
962,823
50,323
Series
C-1 Convertible Preferred stock
-
19,609
Convertible
notes
285,429
466,201
Total
1,248,252
536,133
12
Recent
Accounting Pronouncements
In
December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU
2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions
to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance
is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption
permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.
In
August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity’s Own Equity , which simplifies accounting for convertible instruments by removing major separation models required under
current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope
exception and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is effective for fiscal years,
and interim periods within those fiscal years, beginning after December 15, 2021, with early adoption permitted. The Company is currently
evaluating the impact of this standard on its financial statements and related disclosures.
Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s
present or future financial statements.
Note
5 - Note Payable
2020
December Promissory Note (Retired)
On
December 16, 2020, the Company issued Cavalry Fund I LP (“Cavalry”) a $ 1,000,000 promissory note (the “2020 December
Promissory Note”) in consideration for $ 1,000,000 . The 2020 December Promissory Note is (i) due on October 16, 2021 , (ii) convertible
at a 35 % discount to the closing price of the Company’s common stock on the date before exercise with a floor price of $ 0.40 per
share and (iii) shall bear interest at 12 % per annum (payable at maturity). Subject to certain limitations, the Company may force conversion
of the 2020 December Promissory Note. In connection with issuance of the 2020 December Promissory Note, the Company issued a Series C
warrant to purchase 200,000 shares of the Company’s common stock at an exercise price of $ 2.00 , the Series C warrants were exercised
for cash on January 15, 2021, resulting in proceeds of $ 400,000 to the Company.
During
the nine months ended September 30, 2021, the Company recorded approximately $ 868,000 amortization of debt discount related to the 2020
December Promissory Note.
During
the nine months ended September 30, 2021, the Company recorded interest expense of approximately $ 88,000 for the 2020 December Promissory
Note.
On
September 24, 2021, the Company paid off in full the 2020 December Promissory Note. Repayment to Cavalry consisted of $ 1,000,000 in principal
and $ 92,712 in accrued interest, for a total of $ 1,092,712 . Cavalry confirmed the 2020 December Promissory Note had been fully paid and
the Company has no further obligations with respect to the note.
2021
January Promissory Note
On
January 15, 2021, the Company issued Calvary a $ 1,000,000 promissory note (the “2021 Promissory Note”) in consideration for
$ 1,000,000 . The 2021 Promissory Note is (i) due on November 15, 2021 , (ii) convertible at a 35 % discount to the closing price of the
Company’s common stock on the date before exercise with a floor price of $ 7.50 per share and (iii) shall bear interest at 12 % per
annum (payable at maturity). Subject to certain limitations, the Company may force conversion of the 2021 Promissory Note.
In
connection with issuance of the 2021 Promissory Note, the Company issued a Series D warrant to purchase 200,000 shares of the Company’s
common stock at an exercise price of $ 21.60 per share (the “Series D Warrant”). Detachable warrants issued in a bundled transaction
with debt and equity offerings are accounted for on a separate basis. The allocation of the issuance proceeds to the base instrument
and to the warrants depends on the accounting classification of the separate warrant as equity or liability. If the warrants are classified
as equity, then the allocation is made based upon the relative fair values of the base instrument and the warrants following the guidance
in ASC 470-20-25-2. In this case, the Series D Warrant is equity-classified, with the fair value at issuance was approximately $ 3,580,000 .
As such, the Company recognized a beneficial conversion feature, resulting in a discount to the 2021 Promissory Note of approximately
$ 782,000 with a corresponding credit to additional paid-in capital.
13
In
addition, the 2021 Promissory Note does not contain any embedded features that require bifurcation pursuant to ASC 815-15. At the issuance
date, the 2021 Promissory Note was convertible into 70,572 shares of common stock at $ 14.10 per share, but the Company’s fair value
of underlying common stock was $ 21.8 per share. As such, the Company recognized a beneficial conversion feature, resulting in an additional
discount to the 2021 Promissory Note of approximately $ 218,000 with a corresponding credit to additional paid-in capital.
During
the nine months ended September 30, 2021, the Company recorded approximately $ 848,000 amortization of debt discount related to the 2021
Promissory Note.
During
the nine months ended September 30, 2021, the Company recorded interest expense of approximately $ 85,000 for the 2021 Promissory Note.
As of September 30, 2021, the principal balance of the 2021 Promissory Note was $ 1 million and accrued interest on the note payable amounted
to approximately $ 85,000 .
Note
6 - Fair Value of Financial Assets and Liabilities
Financial
instruments, including cash and cash equivalents, accounts and other receivables, accounts payable and accrued liabilities are carried
at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the
fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a
liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market
participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs
when measuring fair value.
The
Company uses three levels of inputs that may be used to measure fair value:
Level
1 - quoted prices in active markets for identical assets or liabilities
Level
2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable
Level
3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)
The
following table presents the Company’s assets and liabilities that are measured at fair value at September 30, 2021 and December
31, 2020:
Schedule
of Fair Value of Assets and Liabilities Valued on Recurring Basis
Fair
value measured at September 30, 2021
Total
at September 30,
Quoted
prices in active markets
Significant
other observable inputs
Significant
unobservable inputs
2021
(Level
1)
(Level
2)
(Level
3)
Liabilities
Warrant
Liabilities
$ 3,705,000
$ -
$ -
$ 3,705,000
Fair value measured at December 31, 2020
Total at December 31,
Quoted prices in active markets
Significant other observable inputs
Significant unobservable inputs
2020
(Level 1)
(Level 2)
(Level 3)
Liabilities
Warrant Liabilities
$ -
$ -
$ -
$ -
14
Level
3 Valuation Techniques
Level
3 financial liabilities consist of the warrant liabilities for which there is no current market for these securities such that the determination
of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair
value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.
A
significant decrease in the volatility or a significant decrease in the Company’s stock price, in isolation, would result in a
significantly lower fair value measurement. Changes in the values of the warrant liabilities are recorded in “change in fair value
of warrant liabilities” in the Company’s statements of operations.
On
March 2, 2021, the Company entered into a securities purchase agreement (the “Offering”) with certain purchasers pursuant
to which the Company agreed to sell an aggregate of (i) 950,000 shares of common stock, and (ii) common stock warrants (the “Warrants”)
to purchase up to 712,500 shares of common stock for gross proceeds of $ 9.5 million in a private placement. The closing of the Offering
occurred on March 4, 2021.
The
Warrants require, at the option of the holder, a net-cash settlement following certain fundamental transactions (as defined in the Warrants)
at the Company. At the time of issuance, the Company maintained control of certain fundamental transactions and as such the Warrants
were initially classified in equity. As of September 30, 2021, the Company no longer maintained control of certain fundamental transactions
as they did not control a majority of shareholder votes. As such, the Company may be required to cash settle the Warrants if a fundamental
transaction occurs which is outside the Company’s control. Accordingly, the Warrants are classified as liabilities. The Warrants
have been recorded at their fair value using the Black-Scholes valuation model, and will be recorded at their respective fair value at
each subsequent balance sheet date. This model incorporates transaction details such as the Company’s stock price, contractual
terms, maturity, risk free rates, as well as volatility.
15
The
Warrants require the issuance of registered shares upon exercise, do not expressly preclude an implied right to cash settlement and are
therefore accounted for as derivative liabilities. The Company classifies these derivative warrant liabilities on the balance
sheet as a current liability.
A
summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company’s
warrant liabilities that are categorized within Level 3 of the fair value hierarchy at the date of issuance and, as of September 30,
2021, is as follows:
Summary
of Valuation Methodology and Significant Unobservable Inputs Warrant Liabilities
September
14, 2021
September
30, 2021
Risk-free
rate of interest
0.79 %
0.98 %
Expected
volatility
192.2 %
169.4 %
Expected
life (in years)
4.47
4.43
Expected
dividend yield
-
-
The
risk-free interest rate was based on rates established by the Federal Reserve Bank. For the Warrants, the Company estimates expected
volatility giving primary consideration to the historical volatility of its common stock. The general expected volatility is based on
the standard deviation of the Company’s underlying stock price’s daily logarithmic returns. The expected life of the warrants
was determined by the expiration date of the warrants. The expected dividend yield was based on the fact that the Company has not historically
paid dividends on its common stock and does not expect to pay dividends on its common stock in the future.
The
following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities for the nine
months ended September 30, 2021 and 2020, that are measured at fair value on a recurring basis:
Schedule
of Changes in Fair Value and Other Adjustments of Warrants
Fair
Value of Level 3 financial liabilities
September
30,
September
30,
2021
2010
Beginning
balance
$ -
$ -
Warrant
liabilities classification
5,771,250
-
Fair
value adjustment of warrant liabilities
( 2,066,250 )
-
Ending
balance
$ 3,705,000
$ -
Note
7 - Stockholders’ Equity
Preferred
Stock
The
Company is authorized to issue up to 2,000,000 shares of preferred stock. This preferred stock may be issued in one or more series, and
shall have such designations, preferences and relative, participating, optional or other special rights and qualifications, limitations
or restrictions thereof as shall be determined at the time of issuance by the Company’s board of directors without further action
by the Company’s shareholders.
On
January 1, 2021, members of the Company’s management subscribed for 110,000 shares of the Company’s Series C-2 Convertible
Preferred Stock (the “Series C-2”), for a total of $ 1,100,000 at $ 10.00 per Share of Series C-2. The Company obtained an
independent valuation of the Series C-2 and $ 179,277 of compensation expense was recognized, representing the difference between the
fair value and the proceeds received.
The
Series C-2 is not mandatorily redeemable and is not unconditionally redeemable. The Series C-2 is callable by the Company. The Certificate
of Designation required that the Company, within 180 days of the Initial Issuance Date, call a special meeting of stockholders seeking
shareholder ratification of the issuance of the Series C-2. If the ratification of the issuance was not approved prior to the twelve-month
anniversary of the Initial Issuance Date (the “Vote Deadline”), the Series C-2 would be redeemed at a price equal to 107 %
of (i) the Stated Value per share plus (ii) all unpaid dividends thereon. Provided; further, if the Company had filed a proxy with the
SEC prior to the Vote Deadline but was unable to conduct a vote prior to the Vote Deadline then the Vote Deadline would have been extended
until such time as the vote was conducted. The Series C-2 holders were not entitled to vote on the ratification. The call provision would
have been automatically triggered if the ratification of the issuance was not approved in a special meeting of stockholders prior to
the twelve-month anniversary of the Initial Issuance Date. The Company held the meeting within the required period and the Series C-2
is no longer redeemable.
16
Based
on the guidance in ASC 480-10-S99 (“ASR 268”), a redeemable equity instrument is not to be included in permanent equity.
Rather, it should be reported between long-term debt and stockholders’ equity, without a subtotal that might imply it is a part
of stockholders’ equity (i.e., “temporary equity” or “mezzanine capital”). ASR 268 specifies that redeemable
stock is any type of equity security, including common or preferred stock, when it has any condition for redemption which is not solely
within the control of the issuer without regard to probability.
The
Series C-2 Certificate of Designation required the Company to redeem the Series C-2 if stockholder approval was not received by the Vote
Deadline. Stockholder approval was not considered to be “solely within the Company’s control.” Stockholder approval
occurred on March 31, 2021, at which time the Series C-2 was no longer callable by the Company. As such, the Series C-2 was initially
classified in temporary equity under ASR 268 and was reclassified to permanent equity upon stockholder approval on March 31, 2021.
The
holders of Series C-2 shall be entitled to receive dividends or distributions on each share of Series C-2 on an “as-converted basis”
into common stock when and if dividends are declared on the common stock by the Board of Directors. Dividends shall be paid in cash or
property, as determined by the Board of Directors.
At
any time or times on or after the two-year anniversary of the Initial Issuance Date, each Holder shall be entitled to convert any portion
of the outstanding Series C-2 held by such Holder into validly issued, fully-paid and non-assessable shares of Common at the Conversion
Rate. The Conversion Amount is subject to adjustment for certain capitalization and Anti-Dilution Events. The Series C-2 will automatically
be converted at the earlier of: (i) the four-year anniversary of the Initial Issuance Date, and (ii) simultaneously with the Company’s
common stock being listed on a national securities exchange. The Conversion Rate is based upon the Conversion Price of $ 1.70 which resulted
in a beneficial conversion feature at the time of issuance. As such, the Company recognized a beneficial conversion amount of $ 129,412
as a reduction to the carrying amount of the convertible instrument. This discount will be amortized as a dividend over two years, the
earliest conversion date. Upon the conversion of Series C-2 into common stock on September 14, 2021, the total amortization of the beneficial
conversion feature is $ 45,541 and the remaining discount is netted against additional paid in capital.
The
Conversion Amount may be adjusted due to certain Anti-Dilution Events. If at any time after the Initial Issuance Date, the Company raises
capital equal to or in excess of $5 million by issuing common stock or Common Stock Equivalents then the Anti-Dilution Amount per share
of Series C-2 shall be the product of: (i) 0.0000004, and (ii) the aggregate amount of all capital raised by the Company after the Initial
Issuance Date (the “Capital Raised”). Provided; further, for the determination of the Anti-Dilution Amount, the amount of
Capital Raised shall be limited to $13 million, regardless of how much capital the Company raises. In the event capital is raised simultaneous
with a listing on a national securities exchange and the automatic conversion of the Series C-2 then such funds shall be included in
the Capital Raised for the purpose of determining the Anti-Dilution Amount. As of September 30, 2021, over $13 million of capital
was raised and the adjustment to the Conversion Amount was fully triggered. The Company recognized the effect of the down-round protection
when capital raises occur as the difference between: (1) the financial instrument’s fair value (without the down round feature)
using the pre-trigger exercise price, and (2) the financial instrument’s fair value (without the down round feature) using the
reduced exercise price. The value of the effect of the down round feature of $5,020,883 was treated as a dividend and a reduction
to income available to common shareholders in the basic EPS calculation. On September 14, 2021, the Series C-2 was converted into 4,011,766
shares of common stock.
Common
Stock
Reverse
Stock Split
On
August 25, 2021, the Company issued 14,477 shares of common stock in connection with the 1-for-10 Reverse Split resulting from the rounding
up of fractional shares of common stock to the whole shares of common Stock.
17
Issuance
of Shares Pursuant to Equity Line of Credit Purchase Agreement
On
January 28, 2021, the Company filed a registration statement on Form S-1 seeking to register 400,000 shares (the “Registration
Statement”) pursuant to the equity line of credit purchase agreement with Cavalry (the “Equity Line Purchase Agreement”).
The Registration Statement was declared effective by the SEC on February 1, 2021.
During
the nine months ended September 30, 2021, the Company issued approximately 321,740 shares of common stock (inclusive of approximately
17,590 pro-rata commitment shares) under the Registration Statement resulting in aggregate net proceeds of $ 3,014,005 (net of
$ 1,000 in transfer agent fees) and $ 3,015,005 in gross proceeds at a per share price of approximately $ 9.37 (inclusive
of the pro-rata commitment shares).
Issuance
of Shares Pursuant to Registered Direct Offering
On
March 4, 2021, the Company entered into a securities purchase agreement (the “RD Purchase Agreement”) with institutional
investors, pursuant to which the Company sold and issued, in a registered direct offering, 950,000
shares of the Company’s common stock, at
a purchase price per share of $ 10.00
and immediately exercisable five-year
warrants to purchase 712,500
shares of common stock at an exercise price of
$ 11.50
per share. Gross proceeds from the Offering was
$ 9.5
million. Net proceeds were $ 8.9
million after deducting placement agent fees
and other offering expenses paid for by the Company.
The
RD Purchase Agreement contains representations, warranties, indemnifications and other provisions customary for transactions of this
nature. Pursuant to the RD Purchase Agreement, subject to limited exceptions, each of the Company and its officers and directors agreed
not to, and not to publicly disclose the intention to, sell or otherwise dispose of, any shares of common stock or any securities convertible
into, or exchangeable or exercisable for, common stock, for a period ending 60 days after the date of the prospectus supplement for this
offering.
The
Company also entered into a placement agent agreement with A.G.P./Alliance Global Partners (“AGP”), pursuant to which AGP
agreed to serve as the exclusive placement agent for the Company in connection with that offering. The Company paid AGP a cash placement
fee equal to 7.0 % of the aggregate gross proceeds raised in the offering (reduced to 3.5 % for certain investors) and reimbursed the placement
agent for its legal fees and other accountable expenses in the amount of $ 40,000 .
At The Market Offering Agreement
On
September 14, 2021, the Company entered into an At-The-Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright
& Co., LLC, as agent (“H.C. Wainwright”), pursuant to which the Company may offer and sell, from time-to-time through
H.C. Wainwright, shares of the Company’s common stock having an aggregate offering price of up to $ 98,767,500 million (the “Shares”).
The Company will pay H.C. Wainwright a commission rate equal to 3.0 % of the aggregate gross proceeds from each sale of Shares.
During
the nine months ended September 30, 2021, the Company sold a total of 41,290 shares of common stock under the ATM Agreement for aggregate
total gross proceeds of approximately $ 279,000 at an average selling price of $ 6.76 per share, resulting in net proceeds of approximately
$ 219,746 after deducting commissions and other transaction costs.
Issuance
of Shares Pursuant to Cash Exercise of Series C Warrants
On
January 15, 2021, the Company issued 200,000 shares of the Company’s common stock to Cavalry upon the exercise of all their Series
C warrants and payment of the exercise amount of $ 400,000 . Cavalry and the Company entered into an agreement whereby Cavalry would exercise
early for cash provided that the Company register the underlying shares of common stock within 30 days of exercise.
18
Issuance
of Shares Due to Conversion of Series C-1 Preferred Stock
On
March 30, 2021, the Company issued 19,609 shares of common stock upon the conversion of 29,414 shares of Series C-1 Convertible Preferred
stock. After this conversion, there were no Series C-1 shares outstanding so the Company filed a Certificate of Withdrawal with the Secretary
of State of the State of Nevada. The Certificate of Withdrawal eliminated from the Articles of Incorporation of the Company all matters
set forth in the Series C-1.
Issuance
of Shares Due to Conversion of Series C-2 Preferred Stock
On
September 14, 2021, the Series C-2 was converted into 4,011,766 shares of common stock. Please refer to the discussion above.
Issuance
of Restricted Stock to Service Providers
During
the nine months ended September 30, 2021, the Company issued to four service providers a total of approximately 52,800 shares of restricted
common stock, representing a total fair value of $ 0.6 million.
2021
Equity Incentive Plan
The
Company’s 2021 Equity Incentive Plan (the “2021 Plan”) was effective on January 1, 2021 and approved by shareholders
on March 31, 2021. The Company has reserved 2,000,000 shares of common stock for issuance pursuant to the 2021 Plan.
Options
On
January 1, 2021, the Board of Directors of the Company approved the grant of 1.2 million stock options with an exercise price of $ 1.90
under the Company’s 2021 Plan to Messrs. David Garrity a director, and Charles Allen and Michal Handerhan, executive officers and
directors of the Company. Effective as of January 1, 2021, the Company and each optionee executed Stock Option Agreements evidencing
the option grants. While stockholder approval (or ratification) of the grants was not required (under either the Stock Option Agreements
or by the resolutions of the Board of Directors approving such grants), the Board of Directors voluntarily caused the Company to seek
shareholder ratification of the grants to limit any potential exposure to breach of fiduciary duty claims. As a result, based on the
guidance in ASC 718, the date the stockholders ratified the grants (March 31, 2021) is the deemed grant date solely with respect to GAAP
for those stock options. Of the stock options: (i) 480,000 options will vest on January 1, 2022 and (ii) the remaining options vested
(prior to March 31, 2021) based upon the Company’s stock price meeting certain milestones.
On
April 1, 2021, the Company granted 35,000 stock options with an exercise price of $ 10.30 to Charles B. Lee and Carol Van Cleef, directors
of the Company. Of the stock options: (i) 14,000 options will vest on April 1, 2022 and (ii) the remaining 21,000 options vest based
upon the Company’s stock price meeting certain milestones.
The
Company records compensation expense for the 14,000 options granted on April 1, 2021 based on the estimated fair value of the options
on the deemed grant date using the Black-Scholes formula, utilizing assumptions laid out in the table below. The Company uses historical
data to determine exercise behavior, volatility and forfeiture rate of the options. For the 21,000 options granted on April 1, 2021 that
vest based upon the Company’s stock price meeting certain milestones, the Company records compensation expense based on the estimated
fair value of the options using a Monte-Carlo simulation.
The
following weighted-average assumptions were used to estimate the fair value of options granted during the nine months ended 2021 and
2020 for both the Black-Scholes formula and the Monte-Carlo simulation:
Summary
of Weighted-average Assumptions Used to Estimate Fair Value
For
the nine months ended
September
30,
2021
2020
Exercise
price
$ 2.1
-
Term
(years)
2.25 - 3.05
-
Expected
stock price volatility
185.9 %
-
Risk-free
rate of interest
0.34 %
-
19
Expected
Volatility : The Company uses historical volatility as it provides a reasonable estimate of the expected volatility. Historical volatility
is based on the most recent volatility of the stock price over a period of time equivalent to the expected term of the option.
Risk-Free
Interest Rate : The risk-free interest rate is based on the U.S. treasury zero-coupon yield curve in effect at the time of grant for
the expected term of the option.
Expected
Term : The Company’s expected term represents the weighted-average period that the Company’s stock options are expected
to be outstanding. The expected term is based on the expected time to post-vesting exercise of options by employees. The Company uses
historical exercise patterns of previously granted options to derive employee behavioral patterns used to forecast expected exercise
patterns.
For
awards vesting upon the achievement of a service condition, compensation cost measured on the grant date will be recognized on a straight-line
basis over the vesting period. For awards vesting upon the achievement of the market conditions which were met at the date of grant,
compensation cost measured on the date of grant was immediately recognized. For awards vesting upon the achievement of the market conditions
which were not met at the date of grant, compensation cost measured on the grant date will be recognized on a straight-line basis over
the vesting period based on estimation using a Monte-Carlo simulation.
A
summary of options activity under the Company’s stock option plan for nine months ended September 30, 2021 is presented below:
Summary
of Option Activity
Number
of Shares
Weighted
Average Exercise Price
Total
Intrinsic Value
Weighted
Average Remaining Contractual Life (in years)
Outstanding
as of December 31, 2020
-
$ -
$ -
-
Employee
options granted
1,235,000
2.14
4,188,000
4.5
Outstanding
as of September 30, 2021
1,235,000
$ 2.14
$ 4,188,000
4.5
Options
vested and exercisable
720,000
$ 1.90
$ 2,512,800
4.5
RSUs
On
January 1, 2021, the Board of Directors of the Company approved 275,000 restricted stock unit grants under the Company’s 2021 Equity
Incentive Plan to Messrs. David Garrity a director, and Charles Allen and Michal Handerhan, executive officers and directors of the Company.
Effective as of January 1, 2021, the Company and each recipient executed a Restricted Stock Agreement evidencing the stock grants. While
stockholder approval (or ratification) of the grants was not required (under either the Restricted Stock Agreements or by the resolutions
of the Board of Directors approving such grants), the Board of Directors voluntarily caused the Company to seek shareholder ratification
of the grants to limit any potential exposure to breach of fiduciary duty claims. As a result, based on the guidance in ASC 718, the
date the stockholders ratified the grants (March 31, 2021) is the deemed grant date solely with respect to GAAP for those restricted
stock grants. The restricted stock units vest when the Company lists its common stock on a national securities exchange. As of September
30, 2021, all 275,000 restricted stock units vested with a total fair value of approximately $ 2.8 million. The cost of stock-based compensation
for restricted stock units is measured based on the closing fair market value of the Company’s common stock at the deemed grant
date and was recorded on the September 14, 2021 vesting date when the listing occurred.
On
April 1, 2021, the Company granted a total of 15,000
restricted stock units to two non-employee
directors of the Company. The restricted stock units vest when the Company lists its common stock on a national securities exchange.
As of September 30, 2021, all 15,000
restricted stock units vested with a total fair
value of approximately $ 0.2
million. The cost of stock-based compensation
for restricted stock units is measured based on the closing fair market value of the Company’s common stock at the deemed grant
date and was recorded on the September
14, 2021 vesting date when the listing occurred.
20
On
June 28, 2021, the Company granted 50,781
restricted stock units to the Company’s
then Chief Financial Officer. The
restricted stock units were to vest over a five-year period as follows: 20 % of the 50,781 restricted stock units were to
vest on the one-year anniversary of the grant date, and the remaining 80% were to vest monthly over the following four years with
vesting occurring on the last day of each respective month. The
grant date fair value of restricted stock units was approximately $ 0.3
million.
A
summary of the Company’s restricted stock units granted under the 2021 Plan during the nine months ended September 30, 2021 are
as follows:
Summary
of Restricted Stock
Number of Restricted Stock Units
Weighted Average Grant Day Fair Value
Nonvested at December 31, 2020
-
$ -
Granted
340,781
9.72
Vested
( 290,000 )
10.29
Nonvested at September 30, 2021
50,781
$ 6.42
Stock-based
Compensation
Stock-based
compensation expense for the nine months ended September 30, 2021 was approximately $ 13.8 million, comprised of $ 203,000 restricted common
stock issued to service providers not pursuant to the 2021 Plan and approximately $ 10.3 million in connection with options issued pursuant
to the 2021 Plan. Unrecognized compensation expense for the Company was $ 2.0 million on September 30, 2021. Stock-based compensation
expense is recorded as a part of selling, general and administrative expenses, compensation expenses and cost of revenues.
Stock-based compensation
expense for the three and nine months ended September 30, 2021 and 2020 was as follows:
Schedule of Stock-based Compensation Expense
Three Months Ended September 30,
Nine Months Ended September 30,
2021
2020
2021
2020
Employee stock option awards
$ 1,638,516
$ -
$ 10,298,844
$ -
Employee restricted stock units awards
3,027,665
-
3,029,040
-
Non-employee restricted stock awards
75,000
-
237,806
-
Series C-2 allocation
-
-
179,277
-
$ 4,741,181
$ -
$ 13,744,967
$ -
Note
8 - Employee Benefit Plans
The
Company maintains defined contribution benefit plans under Section 401(k) of the Internal Revenue Code covering substantially all qualified
employees of the Company (the “401(k) Plan”). Under the 401(k) Plan, the Company may make discretionary contributions of
up to 100 % of employee contributions. During the nine months ended September 30, 2021, the Company made contributions to the 401(k) Plan
of $ 39,000 .
Note
9 - Subsequent Events
From
October 1, 2021 to November 4, 2021, the Company sold a total of 172,547 shares of common stock under the ATM Agreement for aggregate
total gross proceeds of $ 1,185,474 at an average selling price of $ $ 6.87 per share, resulting in net proceeds of approximately $ 1,147,886
after deducting commissions and other transaction costs.
On
October 25, 2021, the Company received a filing acknowledgment with respect to a Certificate of Withdrawal with the Secretary of State
of the State of Nevada. The Certificate of Withdrawal, was effective on October 25, 2021, and eliminated from the Articles of Incorporation
of the Company all matters set forth in the Company’s Certificate of Designation with respect to the Company’s Series C-2
Preferred Stock that had been previously filed with the Secretary of State of the State of Nevada on January 5, 2021. No shares of the
Series C-2 Preferred Stock were issued and outstanding at the time of the filing of the Certificate of Withdrawal, and none will be issued.
On
November 4, 2021, Mr. Andrew Lee resigned as the Company’s Chief Financial Officer. In connection with the resignation, Mr. Charles
Allen was appointed interim Chief Financial Officer.
21
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.